This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zhou, Z. Articles by Kleinerman, E. S. Search for Related Content PubMed PubMed Citation Articles by Zhou, Z. Articles by Kleinerman, E. S.

---

Angiogenesis, Metastasis, and the Cellular Microenvironment

VEGF₁₆₅, but not VEGF₁₈₉, Stimulates Vasculogenesis and Bone Marrow Cell Migration into Ewing's Sarcoma Tumors In vivo

Division of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Eugenie S. Kleinerman, Division of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Unit 87, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-8110; Fax: 713-794-5042. E-mail: ekleiner{at}mdanderson.org

We previously showed that bone marrow stem cells participate in the tumor vessel expansion that supports the growth of Ewing's sarcoma tumors in vivo. The purpose of this study was to determine the relative importance of two isoforms of vascular endothelial growth factor (VEGF) in tumor vessel expansion and recruitment of bone marrow–derived cells during tumor growth. We injected VEGF₁₆₅-siRNA–transfected cells (TCsi/7-1), control siRNA–transfected cells (TC/si-control), or TC71 parental Ewing's sarcoma cells into nude mice. The TCsi/7-1 tumors were then treated with adenoviral vectors expressing VEGF₁₆₅ (Ad-VEGF₁₆₅), VEGF₁₈₉ (Ad-VEGF₁₈₉), or ß-galactosidase (Ad-ß-gal). Bone marrow cells labeled with fluorescent tracker dye were injected into the mice 3 weeks later. The TCsi/7-1 tumors were significantly smaller (P < 0.05), had decreased vessel density, and showed significantly lower bone marrow cell migration than did TC71 parental and TC/si-control tumors. Treatment with Ad-VEGF₁₆₅, but not Ad-VEGF₁₈₉ or Ad-ß-gal, resulted in a significant increase in bone marrow cell infiltration, tumor vessel density, and tumor growth. Immunohistochemical staining revealed that the injected bone marrow cells migrated to and incorporated into the expanding CD31⁺ tumor vessel network. Taken together, these data show that VEGF₁₆₅ is a chemoattractant that recruits bone marrow cells into the tumor area. These data provide a mechanism by which Ewing's sarcoma cells induce vasculogenesis. (Mol Cancer Res 2007;5(11):1125–32)